CITIUS ONCOLOGY, INC. - 8-K Filing Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Citius Oncology, Inc. (Nasdaq: CTOR) on April 22, 2026. The Company is an emerging growth company incorporated in Delaware with principal executive offices in Cranford, NJ.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on a regulatory listing matter.
Material Changes and Events
On April 22, 2026, Nasdaq notified the Company that its common stock bid price had closed below the minimum $1.00 per share requirement for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). The stock remains listed on the Nasdaq Capital Market under the symbol "CTOR" pending compliance actions.
Outlook, Risks, and Contingencies
- Compliance Period: The Company has 180 calendar days, until October 19, 2026, to regain compliance.
- Compliance Criteria: To cure the deficiency, the bid price must close at $1.00 or more for 10 consecutive business days before the deadline.
- Secondary Compliance Option: If the initial period expires without compliance, the Company may be eligible for an additional 180-day period. This requires meeting the market value of publicly held shares and other initial listing standards, potentially necessitating a reverse stock split.
- Delisting Risk: Failure to regain compliance by the required deadlines may result in delisting. The Company may appeal such a determination to a Nasdaq hearings panel.
- Management Commentary: The Company is evaluating options to regain compliance but states there can be no assurance of success.
Investor Verification Checklist
- Verify the current trading price of CTOR to assess the gap from the $1.00 threshold.
- Monitor the Company's announcements regarding a potential reverse stock split to meet market value requirements.
- Review the Company's cash position to ensure it can fund operations and potential restructuring costs during the compliance period.
- Track the 10-day consecutive closing price requirement leading up to the October 19, 2026 deadline.